Zynerba Pharma CS (ZYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 35,968 | 44,400 | 50,641 | 55,935 | 62,490 |
| Receivables | 1,309 | 1,175 | 1,225 | 1,379 | 1,474 |
| TOTAL | $39,295 | $47,576 | $54,775 | $60,801 | $65,672 |
| Non-Current Assets | |||||
| PPE Net | 395 | 473 | 410 | 420 | 323 |
| Other Non-Current Assets | 787 | 587 | 336 | 1,146 | 1,013 |
| TOTAL | $1,182 | $1,060 | $746 | $1,566 | $1,335 |
| Total Assets | $40,477 | $48,637 | $55,521 | $62,367 | $67,007 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,479 | 2,142 | 1,943 | 1,620 | 1,675 |
| Accrued Expenses | 8,759 | 7,251 | 7,015 | 7,598 | 7,641 |
| TOTAL | $11,456 | $9,610 | $9,173 | $9,431 | $9,528 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 60 | 120 | 179 | 237 |
| TOTAL | $N/A | $60 | $120 | $179 | $237 |
| Total Liabilities | $11,456 | $9,670 | $9,292 | $9,610 | $9,765 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 53,939 | 53,652 | 53,352 | 47,063 | 45,753 |
| Common Shares | 54 | 54 | 48 | 47 | 44 |
| Retained earnings | -295,407 | -284,631 | -274,517 | -266,501 | -257,825 |
| TOTAL | $29,021 | $38,967 | $46,229 | $52,757 | $57,242 |
| Total Liabilities And Equity | $40,477 | $48,637 | $55,521 | $62,367 | $67,007 |